# DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

> **NCT06364917** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 24 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06364917
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-04-27
- **Final completion:** 2027-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364917, "DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06364917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*